October 04, 2022
Merck has launched a suit claiming a New Jersey-based pharmaceutical company's proposed generic of the blockbuster diabetes drug Januvia infringes its patent on the treatment, less than a week after the Federal Circuit backed a Patent Trial and Appeal Board decision upholding the patent.